[Correspondence] Bisphosphonates in osteoporosis: NICE and easy?

The recent National Institute for Health and Care Excellence (NICE) updated multiple technology appraisal on bisphosphonate use in osteoporosis1 demonstrates how, for a common disorder, the strict application of cost-effectiveness thresholds for inexpensive drugs might lead to counterintuitive and potentially harmful guidance. The multiple technology appraisal incorporates the development of fracture risk calculators based on individualised clinical risk factors, such as FRAX and QFracture (recommended by NICE for the assessment of fracture risk in some sections of the population2), and the availability of low-cost generic forms of oral and intravenous bisphosphonates.
Source: LANCET - Category: General Medicine Authors: Tags: Correspondence Source Type: research